TY - JOUR
T1 - Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment
AU - Shah, Ajit K.
AU - Brundage, Richard C.
AU - Gratwohl, Alois
AU - Sawchuk, Ronald J.
PY - 1992/6
Y1 - 1992/6
N2 - The objective of this study was to examine the concentrations in blood of cyclosporine (CyA) in rabbits during chronic subcutaneous (sc) administration and to propose a model that describes these data. Ten rabbits received sc CyA at 15 mg/kg daily for 1 week, then at 20 mg/kg twice weekly for 3 weeks, and at 15 mg/kg twice weekly for 7 weeks. Concentrations in blood were obtained weekly during the dosing period, and three to five concentrations were obtained over a 5‐week period after dosing was terminated. CyA blood concentration‐time (concentration in blood versus time) profiles could not be adequately described by absorption from a single dosing compartment. A two‐compartment, sc absorption‐site model was postulated. Steady‐state concentrations in blood from three additional rabbits that had received CyA at 16.8 μg/min as a constant‐rate intravenous infusion were added to the data set. A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day−1 (10.0), K21 = 0.0109 day−1 (12.6), Ka = 0.0807 day−1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (Fis bioavailability), and Vd/F is the apparent volume of distribution of CyA. The interindividual variability in CL/Fwas estimated as 20.5% (41.2), and the residual variability was 25.8% (15.6). The sc administration of CyA appears to provide slow, but very significant, absorption in rabbits.
AB - The objective of this study was to examine the concentrations in blood of cyclosporine (CyA) in rabbits during chronic subcutaneous (sc) administration and to propose a model that describes these data. Ten rabbits received sc CyA at 15 mg/kg daily for 1 week, then at 20 mg/kg twice weekly for 3 weeks, and at 15 mg/kg twice weekly for 7 weeks. Concentrations in blood were obtained weekly during the dosing period, and three to five concentrations were obtained over a 5‐week period after dosing was terminated. CyA blood concentration‐time (concentration in blood versus time) profiles could not be adequately described by absorption from a single dosing compartment. A two‐compartment, sc absorption‐site model was postulated. Steady‐state concentrations in blood from three additional rabbits that had received CyA at 16.8 μg/min as a constant‐rate intravenous infusion were added to the data set. A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day−1 (10.0), K21 = 0.0109 day−1 (12.6), Ka = 0.0807 day−1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (Fis bioavailability), and Vd/F is the apparent volume of distribution of CyA. The interindividual variability in CL/Fwas estimated as 20.5% (41.2), and the residual variability was 25.8% (15.6). The sc administration of CyA appears to provide slow, but very significant, absorption in rabbits.
UR - http://www.scopus.com/inward/record.url?scp=0026701885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026701885&partnerID=8YFLogxK
U2 - 10.1002/jps.2600810602
DO - 10.1002/jps.2600810602
M3 - Article
C2 - 1522483
AN - SCOPUS:0026701885
SN - 0022-3549
VL - 81
SP - 491
EP - 495
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 6
ER -